# Prevalence of SARS-CoV-2 infection and immunity in a New York county in 2022 reveals frequent asymptomatic or undiagnosed infections

**Authors:** Casey L. Cazer, Jeanne W. Lawless, Parshad Mehta, Bettina Wagner, Diego G. Diel, Katherine R. McLaughlin, Jeffrey W. Bethel, Elizabeth F. Plocharczyk, Kevin J. Cummings, Genevive R. Meredith, Samantha Hillson, Robert Lawlis, Lara Parrilla, Benjamin D. Dalziel, Harapan Harapan, Harapan Harapan, Harapan Harapan, Harapan Harapan, Harapan Harapan

PMC · DOI: 10.1371/journal.pone.0323659 · PLOS One · 2025-05-28

## TL;DR

A study in a New York county found many people had SARS-CoV-2 antibodies without knowing, showing frequent asymptomatic or undiagnosed infections in 2022.

## Contribution

The study provides local prevalence estimates of SARS-CoV-2 infection and immunity using a representative sample and highlights the role of asymptomatic cases.

## Key findings

- PCR-positive test prevalence was under 5%, but half the population had antibodies from prior infection.
- Most individuals (81-92%) had antibodies from infection or vaccination, indicating high immunity levels.
- County-level reported infection rates were lower than antibody survey results, suggesting many undiagnosed cases.

## Abstract

Accurate and timely surveillance of SARS-CoV-2 prevalence and immunity is critical to local and national COVID-19 pandemic responses. Representative surveillance surveys reveal more accurate estimates of COVID-19 infection than other measures based on reported test results. Our main research objectives were (i) to provide local health department officials with prevalence estimates calculated from a representative sample to better inform their decision-making efforts in response to the COVID-19 pandemic and (ii) to identify characteristics associated with COVID-19 infections among high-risk groups. Three municipalities were sampled at one timepoint (February, April, or October 2022) using a 2-stage cluster sampling design. Participants provided anterior nares swabs, which were tested for SARS-CoV-2 with a RT-PCR and for nucleocapsid protein and receptor binding domain antibodies by multiplex Luminex assay. Participants completed a survey on socio-demographics, SARS-CoV-2 prevention behaviors and attitudes, and vaccination and infection history. A total of 233 individuals from 221 households provided anterior nares swabs, and 215 samples were linked to survey data. After adjusting for study design, the household prevalence of PCR-positive tests was less than 5%, but approximately half of the population had antibodies from a prior infection and most (81% to 92%) had antibodies from either infection or vaccination. Discrepancies between self-reported positive test and vaccination status and antibody results suggested a high prevalence of asymptomatic infection and waning antibody titers. County-level infection prevalences, estimated from the county test reporting system, were 16.6% in February, 19.1% in April, and 23.8% in October, substantially lower than the prevalence of individuals with antibodies from infection in the surveys, also supporting a high prevalence of asymptomatic or unconfirmed infections. The overall small sample size precluded an analysis of characteristics associated with active or past infection. In conclusion, surveillance surveys can provide timely data on infection status and immunity to support public health responses.

## Linked entities

- **Proteins:** nucleocapsid protein (nucleocapsid protein)
- **Diseases:** COVID-19 (MONDO:0100096)

## Full-text entities

- **Diseases:** infection (MESH:D007239), COVID-19 (MESH:D000086382)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12118914/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12118914/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12118914/full.md

---
Source: https://tomesphere.com/paper/PMC12118914